Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV003991476 | SCV004809143 | likely pathogenic | Recombinase activating gene 2 deficiency | 2024-04-01 | reviewed by expert panel | curation | The c.1332C>G (NM_000536.4) variant in RAG2 is a missense variant predicted to cause the substitution of Isoleucine by Methionine at amino acid 444 (p.Ile444Met). This variant is absent from gnomAD v4 (PM2_Supporting). This variant is located in the PHD domain, amino acids 414-487 of RAG2, which is defined as a critical functional domain by the ClinGen SCID VCEP (PMID: 26996199); PM1. The recombination activity assay showed activity of this variant compared to wildtype RAG2 is 2.7% (SEM 0.3), which is lower than the SCID VCEP threshold (<25%) for PS3_Moderate, meeting this criterion (PS3_Moderate, PMID 29772310). Diagnostic criteria for SCID/Leaky SCID/Omenn syndrome met 0.5 pts T-B-NK+ lymphocyte subset profile 0.5 pts, the total is 1 point, PP4 is met (Same patient was reported in PMIDs: 19912631, 29772310, and 32691468). The proband (P32) is homozygous for this variant (0.5 pts; PM3_Supporting; PMID: 29772310). In summary, this variant meets the criteria to be classified as Likely Pathogenic for autosomal recessive recombinase activating gene 2 deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: PM2_Supporting, PM1_Moderate, PS3_Moderate, PP4 and PM3_Supporting. (VCEP specifications version 1.0). |
Pediatric Immunology Service, |
RCV000681595 | SCV000693943 | uncertain significance | Histiocytic medullary reticulosis; Recombinase activating gene 2 deficiency; Inborn error of immunity | 2018-03-06 | criteria provided, single submitter | research | |
Baylor Genetics | RCV001331311 | SCV001523328 | likely pathogenic | Histiocytic medullary reticulosis | 2019-12-18 | criteria provided, single submitter | clinical testing | This variant was determined to be likely pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. |
Center for Genomic Medicine, |
RCV004527390 | SCV005038823 | likely pathogenic | Severe combined immunodeficiency, B cell-negative | 2024-03-14 | criteria provided, single submitter | clinical testing |